Intra-Cellular Therapies Presents Data From The CAPLYTA Adjunctive MDD Phase 3 Program At The American College Of Neuropsychopharmacology Annual Meeting; Data Shows Robust Remission And Response Efficacy Rates In Patients Taking CAPLYTA, As Well As...
Intra-Cellular Therapies Presents Data From The CAPLYTA Adjunctive MDD Phase 3 Program At The American College Of Neuropsychopharmacology Annual Meeting; Data Shows Robust Remission And Response Efficacy Rates In Patients Taking CAPLYTA, As Well As...
Intra-Cellular Therapies Presents Data From The CAPLYTA Adjunctive MDD Phase 3 Program At The American College Of Neuropsychopharmacology Annual Meeting; Data Shows Robust Remission And Response Efficacy Rates In Patients Taking CAPLYTA, As Well As Improvements In Anxiety Symptoms Were Also Observed In Patients Taking CAPLYTA As Measured By The Generalized Anxiety Disorder Questionnaire
Intra-Cellular Therapies在美国神经心理药理学年会上展示了CAPLYTA辅助治疗重度抑郁症第三阶段项目的数据；数据显示，服用CAPLYTA的患者在缓解和反应的有效率上表现良好，同时在服用CAPLYTA的患者中也观察到了焦虑症状的改善，改进通过广泛性焦虑障碍问卷测量。
Presentations complement topline data with new data from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy for the treatment of major depressive disorder
这些展示补充了来自两项关键研究（501和502研究）的新数据，这些研究评估了lumateperone作为重度抑郁症治疗的辅助疗法。
Data shows robust remission and response efficacy rates in patients taking CAPLYTA
数据显示，服用CAPLYTA的患者在缓解和反应的有效率上表现良好。
Robust improvements in anxiety symptoms were also observed in patients taking CAPLYTA as measured by the Generalized Anxiety Disorder Questionnaire (GAD-7)
在服用CAPLYTA的患者中，焦虑症状也得到了显著改善，这一结果通过广泛性焦虑障碍问卷（GAD-7）进行测量。
Pooled safety and tolerability data from Studies 501 and 502 show favorable safety and tolerability profile for CAPLYTA consistent with prior studies
来自501和502研究的合并安全性和耐受性数据显示，CAPLYTA的安全性和耐受性特征与之前的研究一致，表现良好。
A post-hoc analysis from Study 403 in mixed features shows CAPLYTA significantly improved anhedonia symptoms as measured by the MADRS anhedonia factor score
来自403研究的后期分析显示，CAPLYTA显著改善了以MADRS快感缺失因子评分测量的快感缺失症状。
BEDMINSTER, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced presentations at the 63rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP) which included new efficacy, safety, and tolerability analyses from its CAPLYTA adjunctive major depressive disorder (MDD) pivotal program.
新泽西州贝德敏斯特，2024年12月11日（全球新闻社）-- Intra-Cellular Therapies, Inc.（纳斯达克：ITCI），是一家专注于中央神经系统（CNS）疾病治疗药物开发和商业化的生物制药公司，今天在第63届美国神经心理药理学年会上宣布了展示，包括其CAPLYTA辅助重度抑郁症（MDD）关键项目的新有效性、安全性和耐受性分析。
